The latest research report titled ‘Asia Pacific Cardiac Ablation Market Forecast 2028 By Approach, By Product Ablators, By Application, By End-use, Research Report, Country Outlook, COVID-19 Impact Statistics, Country Outlook, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share’, available with MarketStudyReport, cites that Asia Pacific cardiac ablation market is expected to be valued at USD 1.9 billion by the year 2028.

Higher vulnerability to cardiovascular ailments including cardiac arrhythmias in senior citizens, increasing preference for minimally invasive procedures, technological developments in cardiac ablation equipment, and rising healthcare expenditure are all begetting the significant growth of the Asia Pacific cardiac ablation industry.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4966037/  

Furthermore, booming elderly population, and cognizance of cardiac ablation being the effective & safest therapy for treating unusual heart rhythms are also propelling the growth of industry share.

Based on the product type, the industry is segmented into electrical ablators, ultrasound ablators, radiofrequency (RF) ablators, cryoablation devices, and others. Speaking of approach type, Asia Pacific cardiac ablation industry is categorized into open/surgical, and catheter based. 

Moving to application spectrum, the market is classified into tachycardia, atrial fibrillation & flutter, and others. The industry share from atrial fibrillation & flutter segment is expected to be valued at US $900 million by 2028. The growth is attributed to rising incidents of cardiac arrhythmias and atrial fibrillation among individuals caused by unhealthy lifestyle, smoking, and obesity. 

Moving on to end-users, the industry scope includes ambulatory surgical centers, hospitals, cardiac centers, and others. Among these, the hospital segment held 60% market share in 2021 and will continue to garner traction through 2028. Hospital services are the topmost preference of patients due to the availability of technologically advanced cardiac ablation equipment and the experienced staff, backed by inflowing public & private investment.

Regionally, India market is expected to grow with a 15.4% CAGR through 2028. The growth is due to the favorable regulatory conditions set for the advancements in cardiac ablation in the country. Moreover, the country has become the topmost landing place for high-end diagnostic services, owing to the significant investments in advanced diagnostic facilities, as well as inexpensive nature of medical care. 

The major companies influencing Asia Pacific cardiac ablation market dynamics include Japan Lifeline Co., Ltd., MicroPort, Boston Scientific Corporation, Biosense Webster, Inc., AngioDynamics, Inc., Stereotaxis, Inc., Medtronic plc, Biotronik SE & Co. KG, AtriCure, Inc. and Abbott laboratories.